Conferences
5–7 January 2014, Cambridge, UK
Signalling and Acquired Resistance to Targeted Cancer Therapeutics
Tumour cells rapidly evolve to acquire resistance to new, targeted therapeutics such as protein kinase inhibitors. Understanding such ‘acquired resistance’ has obvious clinical relevance but also reveals the plasticity of signalling pathways and their ability to remodel through feedback and cross-talk. This meeting will highlight advances in understanding how tumour cells adapt to inhibition of specific signalling pathways and the role this plays in acquired resistance.
Topics:
- RAF-MEK-ERK signalling
- Tyrosine kinases and their inhibitors
- TOR/PI3K inhibitors
- Kinome reprogramming
- Cell survival/cell death signalling
- Systems and computational biology approaches
